[Guidelines of clinical practice of the SERV (Spanish Retina and Vitreous Society): management of ocular complications of diabetes. Diabetic retinopathy and macular oedema]. / Guías de práctica clínica de la SERV: manejo de las complicaciones oculares de la diabetes. Retinopatía diabética y edema macular.

OBJECTIVE: Diabetes mellitus is considered the most common cause of blindness in the working population of industrialized countries, with diabetic macular edema being the most common cause of decreased visual acuity and proliferative diabetic retinopathy (PDR) being responsible for the most severe visual deficits. We have therefore tried to establish a guide for clinical intervention whose purpose is to provide orientation on the treatment of diabetic retinopathy and its complications. This is necessary at a time when many treatment options have emerged whose role is not yet fully defined. METHOD: A group of expert retina specialists selected by the SERV (Vitreous-Retina Spanish Society) assessed the published results of different treatment options currently available, suggesting lines of action according to the degree of diabetic retinopathy present and the presence or absence of macular edema. RESULTS: PDR is primarily treated with pan-retinal photocoagulation. For clinically significant diabetic macular edema without signs of vitreomacular traction, the treatment of choice continues to be focal/grid photocoagulation. Similarly, retinovitreal surgery is indicated for both conditions. The use of antiangiogenic drugs was also analyzed but remains inconclusive. CONCLUSION: Laser therapy is effective in the management of diabetic retinopathy and diabetic macular edema. The role of antiangiogenics is not yet sufficiently defined.

Guías de Práctica Clínica de la SERV: Manejo de las complicaciones oculares de la diabetes. Retinopatía diabética y edema macular / Guidelines of Clinical Practice of the SERV: Management of ocular complications of diabetes. Diabetic retinopathy and macular oedema

Objetivo: La diabetes mellitus está considerada como la causa más frecuente de ceguera en lapoblación activa en los países industrializados,siendo el edema macular diabético la causa más frecuentede disminución de la agudeza visual y laretinopatía diabética proliferante la responsable delos déficit visuales más severos. Por ello hemosintentado establecer una guía de actuación clínicacuyo propósito es proporcionar unas directrices quesirvan de orientación para el tratamiento de la retinopatía diabética y sus complicaciones. Esto sehace necesario en un momento en el que han aparecidonumerosas alternativas terapéuticas cuyo papelaún no está completamente definido.Método: Un grupo de expertos retinólogos seleccionadospor la SERV han evaluado los resultadospublicados sobre las distintas opciones terapéuticasque existen en la actualidad, en base a lo cual sesugieren líneas de actuación según el grado de retinopatíadiabética que presenta el paciente y la presenciao no de edema macular.Resultados: El tratamiento princeps de la RDP esla panretinofotocoagulación (PFC). El tratamientode elección en el edema macular diabético clínicamentesignificativo sin signos de tracción vítreomacular continúa siendo la fotocoagulaciónfocal/rejilla. La cirugía retinovítrea tiene así mismosus indicaciones en ambas afecciones. Se discute eluso de fármacos antiangiogénicos.Conclusión: La laserterapia es efectiva en el manejode la RD y del EMD. El papel de los antiangiogénicosaún no está suficientemente definido (AU)

Objective: Diabetes mellitus is considered the most common cause of blindness in the working populationof industrialized countries, with diabetic macularedema being the most common cause of decreasedvisual acuity and proliferative diabetic retinopathy(PDR) being responsible for the most severevisual deficits. We have therefore tried to establisha guide for clinical intervention whose purpose is toprovide orientation on the treatment of diabetic retinopathyand its complications. This is necessary at a time when many treatment options have emergedwhose role is not yet fully defined.Method: A group of expert retina specialists selectedby the SERV (Vitreous-Retina Spanish Society)assessed the published results of different treatmentoptions currently available, suggesting lines ofaction according to the degree of diabetic retinopathypresent and the presence or absence of macularedema.Results: PDR is primarily treated with pan-retinalphotocoagulation. For clinically significant diabeticmacular edema without signs of vitreomacular traction,the treatment of choice continues to befocal/grid photocoagulation. Similarly, retinovitrealsurgery is indicated for both conditions. The use ofantiangiogenic drugs was also analyzed but remainsinconclusive.Conclusion: Laser therapy is effective in the managementof diabetic retinopathy and diabetic macularedema. The role of antiangiogenics is not yet sufficiently defined (AU)

[Review of the protocol for the treatment of diabetic retinopathy]. / Revisión del protocolo para el tratamiento de la retinopatía diabética.

We present general guidelines to help us with the treatment of diabetic retinopathy (DR) at a time when numerous therapeutic alternatives have been developed although their role has not yet been adequately defined. This protocol is not directed at experienced retinologists but rather at general ophthalmologists who require a practical and up to date guide of a pathology as prevalent as RD. The different therapeutic options available, and their most accepted indications depending on the degree of diabetic retinopathy that patients have, are reviewed. We propose what to do in cases of mild, moderate and severe non-proliferative diabetic retinopathy as well as in cases of proliferative diabetic retinopathy (panphotocoagulation/antiangiogenic drugs/vitreorretinal surgery). The treatment of diabetic macular edema depending on its angiographic and topographic characteristics is also discussed. The importance of metabolic control of the patient is stressed (tight glycemic control, control of arterial hypertension and dyslipemia) in aiding the treatment of diabetic retinopathy. This therapeutic proposal has been discussed widely by retinologists from the four largest hospitals in the Canary Islands, and is therefore an agreed text based on recent scientific literature.

Revisión del protocolo para el tratamiento de la retinopatía diabética / Revision of the protocol for the treatment of diabetic retinopathy

Se presentan unas directrices generales con el objetivode proporcionar una orientación en el manejo dela retinopatía diabética (RD) en un momento en elque han aparecido numerosas alternativas terapéuticascuyo papel aún no está suficientemente definido.Este protocolo está dirigido no a retinólogos expertossino a oftalmólogos generales que precisen una guíapráctica y actualizada de una patología tan prevalentecomo la RD.En este documento se revisan las distintas opcionesterapéuticas disponibles y su indicación más aceptadasegún el grado de retinopatía diabética que presenteel paciente. Se plantea así que hacer con unaretinopatía diabética no proliferativa (RDNP) leve,moderada (ambas control por su oftalmólogo dezona) y severa (en casos muy seleccionados puedeconsiderarse la realización de una panfotocoagulación–PFC–). Los pacientes con retinopatía diabéticaproliferativa (RDP) serán tratados en los centroshospitalarios (PFC/fármacos antiangiogénicos/cirugía vítreorretiniana –CVR–) hasta que sea controladosu proceso. Se discute asimismo el tratamientodel edema macular (EM) diabético según sus característicasangiográficas y topográficas.Se hace hincapié en la importancia del control metabólicodel paciente (optimizar el control glucémico,de su hipertensión arterial y de la dislipemia) comotratamiento necesario y coadyuvante de su RD.Esta propuesta terapéutica ha sido ampliamente discutidapor retinólogos de los cuatro grandes hospitalesde Canarias por lo que se trata de un texto consensuadobasado en la bibliografía científica actual(AU)

We present general guidelines to help us with thetreatment of diabetic retinopathy (DR) at a timewhen numerous therapeutic alternatives have beendeveloped although their role has not yet been adequatelydefined. This protocol is not directed atexperienced retinologists but rather at general ophthalmologistswho require a practical and up to dateguide of a pathology as prevalent as RD.The different therapeutic options available, andtheir most accepted indications depending on thedegree of diabetic retinopathy that patients have, arereviewed. We propose what to do in cases of mild,moderate and severe non-proliferative diabetic retinopathyas well as in cases of proliferative diabeticretinopathy (panphotocoagulation/antiangiogenicdrugs/vitreorretinal surgery). The treatment of diabeticmacular edema depending on its angiographicand topographic characteristics is also discussed.The importance of metabolic control of thepatient is stressed (tight glycemic control, control of arterial hypertension and dyslipemia) in aidingthe treatment of diabetic retinopathy.This therapeutic proposal has been discussedwidely by retinologists from the four largest hospitalsin the Canary Islands, and is therefore an agreedtext based on recent scientific literature(AU)

[Neurosensory defects secondary to neonatal hyperbilirubinemia]. / Defectos neurosensoriales secundarios a hiperbilirrubinemia neonatal.

Effects to medium and long term of neonatal hyperbilirubinemia (BI less than or equal to 16.8 mg%) on acoustic and visual sensorial systems have been studied on two groups: a) group I, 20 jaundiced term and 5 jaundiced preterm newborns, 21 of term treated with phototherapy, b) group II, 15 term and 10 preterm newborns. At the age of 9-10 years the following data were analyzed: Anthropometrics, psychometrics, audiologic and ophthalmologic. Statistic analysis of results obtained on the differences that have been studied do not show statistic differences between problem and control series (p greater than 0.05) except for audiological parameters. A higher incidence of hypoacusia was found in group I (p less than 0.05). It is concluded that neonatal hyperbilirubinemia (BI less than or equal to 16.8 mg%) has not any side-effects at medium and long term on the visual area, but it produces hypoacusia.